Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates P38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy

PLoS ONE - United States
doi 10.1371/journal.pone.0023756
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-12 EGFR Therapy in ASCL1 Positive Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology
Forensic MedicinePathology
2008English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology
2014English

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation

Oncology Reports
MedicineCancer ResearchOncology
2007English

Pneumatosis Cystoides Intestinalis After Gefitinib Therapy for Pulmonary Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma

Oncotarget
Oncology
2016English

OA07.06 Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy